Pcsk 9 mAb denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for pcsk9 mab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Requires Step Therapy Before Approving a PCSK9 Monoclonal Antibody

UnitedHealthcare's step-therapy (also called "fail-first") policy for PCSK9 inhibitor monoclonal antibodies requires that a patient demonstrate a documented adequate trial of one or more lower-cost lipid-lowering therapies — most commonly statin-class agents and, depending on the policy, additional agents — before the PCSK9 inhibitor will be covered. This policy exists because statins are effective for most patients and are substantially less expensive. The denial does not mean the PCSK9 inhibitor is inappropriate for you; it means UHC's automated review did not find evidence of the required prior steps in the submitted documentation.

## Why This Denial Is Appealable

Step-therapy denials are among the most successfully appealed denial types when the patient actually has completed the required steps or has a documented clinical reason for exemption (such as a documented intolerance or a contraindication recorded in the chart). ACA §2719 and ERISA §503 apply. Many states also have step-therapy override laws that require plans to grant an exception when a prior-authorization or step requirement would be clinically harmful or when the required step has already been tried. The external-review window is generally 4 months, with an expedited option available.

## The Appeal Process and Timeline

1. Request UHC's step-therapy policy for this drug class: you need to know exactly which agents and trial durations are required before the exception criteria are triggered. 2. Document completed steps: compile pharmacy records and chart notes for every required prior therapy. For each, record the start date, end date or discontinuation date, and the clinical outcome. 3. Document the exemption basis if steps were not completed: your prescriber should explain in writing why a required step was clinically contraindicated or inappropriate. 4. File Level 1 internal appeal within the deadline on the denial notice, attaching all documentation. 5. Request external review if the internal appeal is denied, citing step-therapy override protections if your state law provides them.

## Documentation to Gather

• Pharmacy records: printed dispensing history for all prior lipid-lowering therapies, with dates, quantities, and refill frequency (a consistent refill pattern demonstrates a genuine trial).
• Chart notes documenting outcomes: clinician notes that record the patient's LDL response (or lack of adequate response) and any adverse effects during each prior therapy.
• Statin-intolerance documentation: if the required step was a statin and you could not tolerate it, chart notes recording the adverse effect, any rechallenge, and the prescriber's conclusion are essential.
• Prescriber medical-necessity letter: addresses every required step in UHC's policy — either confirming completion with dates and outcomes, or explaining the clinical basis for exemption.
• UHC's current step-therapy criteria: download and attach as an exhibit, with each criterion annotated to show where in your records it is satisfied.

## Criteria-Mapping Structure

Organize the appeal so that each required step in UHC's policy gets its own section: quote the requirement, then present the pharmacy record dates, chart-note dates, and clinical outcomes that demonstrate completion — or the prescriber explanation for exemption. This parallel structure is the most efficient way to present a step-therapy appeal and leaves the reviewer with no unanswered questions.